Therapeutic options for erythroderma.

In this work we will discuss some of the dilemmas and therapeutic options in the treatment of patients with erythroderma. We will mention treatment modalities for psoriatic erythroderma and review briefly one illustrative case in which a new experimental approach was utilized.

Multiple carcinoma in patients with psoriasis caused by psoralen-ultraviolet A therapy, natural killer cell insufficiency, or intensified sun exposure?

A case is presented of a patient with psoriasis in whom squamous cell carcinoma most likely occurred due to the interaction of various factors (psoralen-ultraviolet A therapy, sun exposure, and suppression of natural killer cell function). Therapy consisted of 1 mg/kg/daily of etretinate (Tegison), which resulted in clearing of psoriatic lesions in one month's time. New carcinomas did not develop and natural killer function improved.